

Amendments to the Claims:

Please cancel Claims 7 and 9 without prejudice or disclaimer, amend Claims 1 and 10, and add new Claims 64-67 as set forth below.

1. (Currently amended) A method for treating an anxiety disorder comprising simultaneously administering to a patient i) pipamperone in a daily dose ranging between 5 and 15 mg and ii) a selective serotonin re-uptake inhibitor (SSRI), of the active ingredient, wherein said simultaneous administration of pipamperone and said SSRI a selective serotonin re-uptake inhibitor (SSRI) is administered to the patient simultaneously with, separate from or sequential to the administration of pipamperone to augments the therapeutic effect of said SSRI or to provides a faster onset of the therapeutic effect of said SSRI, and wherein said SSRI is chosen from the group consisting of CITALOPRAM, fluoxetine, venlafaxine, fluvoxamine, paroxetine, sertraline, milnacipran and duloxetine, or a pro-drug or an active metabolite thereof, or a pharmaceutically acceptable salt thereof.

2-9. (Canceled)

10. (Currently amended) The method of claim 1, wherein said serotonin re-uptake inhibitor is CITALOPRAM and wherein CITALOPRAM is administered in a dose ranging between 10 and 40 mg of the active ingredient.

11-63. (Canceled)

64. (New) A method for treating an anxiety disorder in a patient comprising simultaneously administering to the patient i) pipamperone in a daily dose ranging between 5 and 15 mg and ii) a selective serotonin re-uptake inhibitor (SSRI), wherein said SSRI is chosen from the group consisting of CITALOPRAM, fluoxetine, venlafaxine,

Applicant: Erik Buntinx
Serial No.: 10/752,423
Filed: January 6, 2004
page 3 of 10

fluvoxamine, paroxetine, sertraline, milnacipran and duloxetine, or a pro-drug or an active metabolite thereof, or a pharmaceutically acceptable salt thereof.

65. (New) The method of claim 64, wherein said serotonin re-uptake inhibitor is CITALOPRAM and wherein CITALOPRAM is administered in a dose ranging between 10 and 40 mg.

66. (New) The method of claim 1, where pipamperone and said selective serotonin re-uptake inhibitor (SSRI) are administered in a single pharmaceutical composition or formulation.

67. (New) The method of claim 64, where pipamperone and said selective serotonin re-uptake inhibitor (SSRI) are administered in a single pharmaceutical composition or formulation.